SCHEMBL14693517

SCHEMBL14693517

COc1cc(-c2nn(-c3ccc(N(C)C(=O)C=CCN(C)C)cn3)c3ncnc(N)c23)ccc1C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 1/20 0.41
▸ FGFR2 P21802 1/20 0.41
▸ FGFR3 P22607 1/20 0.41
▸ EGFR P00533 14/20 0.40
▸ BTK Q06187 5/20 0.40
▸ LCK P06239 4/20 0.40
▸ ITK Q08881 4/20 0.40
▸ SRC P12931 13/20 0.40
▸ ABL1 P00519 10/20 0.40
▸ PIK3CD O00329 9/20 0.40
▸ HCK P08631 9/20 0.40
▸ PIK3CA P42336 9/20 0.40
▸ PIK3CB P42338 9/20 0.40
▸ MTOR P42345 9/20 0.40
▸ PIK3CG P48736 9/20 0.40
▸ EPHB4 P54760 9/20 0.40
▸ PRKDC P78527 9/20 0.40
▸ KDR P35968 8/20 0.40
▸ PI4KB Q9UBF8 7/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14693516 1.00 FGFR1 (0.41) FGFR1FGFR2FGFR3EGFRBTK
SCHEMBL14693582 0.90 BTK (0.43) FGFR1FGFR2FGFR3EGFRBTK
SCHEMBL14693583 0.90 BTK (0.43) FGFR1FGFR2FGFR3EGFRBTK
SCHEMBL14706396 0.88 BTK (0.48) FGFR1FGFR2FGFR3EGFRBTK
SCHEMBL14706385 0.88 EGFR (0.42) FGFR1FGFR2FGFR3EGFRBTK
SCHEMBL15086970 0.87 FGFR1 (0.41) FGFR1FGFR2FGFR3EGFRBTK
SCHEMBL14706428 0.86 FGFR1 (0.46) FGFR1FGFR2FGFR3EGFRBTK
SCHEMBL14693575 0.85 SRC (0.46) EGFRBTKLCKITKSRC
SCHEMBL14693576 0.85 SRC (0.46) EGFRBTKLCKITKSRC
SCHEMBL18380711 0.85 FGFR1 (0.43) FGFR1FGFR2FGFR3EGFRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9546172-B2 Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors PHARMACYCLICS LLC (US) 2017-01-17 — — US disclosed
US-9273051-B2 Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors PHARMACYCLICS LLC (US) 2016-03-01 — — US disclosed
US-20130172314-A1 PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PHARMACYCLICS, INC. (US) 2013-07-04 — — US disclosed
WO-2013102059-A1 PYRAZOLO [3, 4-D] PYRIMIDINE AND PYRROLO [2, 3-D] PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PHARMACYCLICS, INC. (US) 2013-07-04 — — WO disclosed
US-8377946-B1 Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors PHARMACYCLICS, INC. (US) 2013-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172314-A1 PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS BTK, LCK, LYN FGFR1 1752/4885FGFR2 983/4885FGFR3 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback